Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475540 | 0.95 | CHRM3 (0.49) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL22766776 | 0.93 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28465528 | 0.89 | CHRM3 (0.52) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26529229 | 0.88 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28471531 | 0.88 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18238558 | 0.88 | CHRM3 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18229046 | 0.84 | CHRM3 (0.53) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL20476343 | 0.83 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25908629 | 0.83 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25908598 | 0.83 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074833-B | Having beta2Benzo ring derivatives with receptor agonistic and M3 receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-107108562-B | With β2ReceptorsNitrogen-containing heterocyclic ring derivative with agonistic and M receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3375781-A1 | BENZO RING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2018-09-19 | — | — | EP | disclosed |
| CN-107108562-A | With β2Nitrogen-containing heterocyclic ring derivative with receptor agonistic and M receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107074833-A | With β2The Benzocyclodirivative of receptor agonism and M3 receptor antagonist activities and its in purposes pharmaceutically | 四川海思科制药有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2017012489-A1 | BENZO RING DERIVATIVE WITH Β2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2017-01-26 | — | — | WO | disclosed |
| WO-2017012489-A1 | BENZO RING DERIVATIVE WITH Β2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2017-01-26 | — | — | WO | disclosed |
| WO-2016180348-A1 | NITROGEN-CONTAINING SPIRO-HETEROCYCLIC DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180348-A1 | NITROGEN-CONTAINING SPIRO-HETEROCYCLIC DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | HCAR2, CHRM3, BDKRB2 | CHRM3 2/4885CHRM2 4/4885CHRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.